CryoLife to purchase German firm Jotec for $225m

MDBR Staff Author Printed 11 October 2017

Medical tool and tissue processing company CryoLife has decided to acquire Germany-based Jotec for around $225m.

According to the deal, CryoLife pays 75% in cash, additionally to issuing 25% of their common stock to Jotec shareholders.

Located in Hechingen, Jotec is involved in the event, production and marketing of medical devices for aortic and peripheral vascular disease.

Their product portfolio includes conventional vascular grafts and interventional implants for vascular and cardiac surgery and radiology and cardiology.

Its products include thoracic stent grafts, abdominal stent grafts and peripheral stent grafts, in addition to interventional accessories.

Additionally, Jotec’s surgical portfolio includes ePTFE vascular grafts and polyester grafts.

 The acquisition allows CryoLife to grow its presence within the endovascular surgical market.

Susceptible to customary closing conditions, the offer is anticipated to accomplish later this season.

CryoLife president and Chief executive officer Pat Mackin stated: “Jotec includes a technologically differentiated product portfolio addressing the $2bn global marketplace for stent grafts utilized in endovascular and open repair of aortic illnesses.  

“Their advanced product portfolio has permitted these to acquire a 17% revenue CAGR in the last 5 years, considerably outpacing the development within the overall European market.”

Jotec Chief executive officer Thomas Bogenschütz stated: “CryoLife is ideally positioned to accelerate adoption in our products through its highly complementary and global cardiac and vascular surgery business.”

Located in suburban Atlanta of Georgia, CryoLife produces, processes and distributes medical devices and implantable living tissues utilized in cardiac and vascular surgical treatments.


Image: CryoLife to get Germany-based Jotec. Photo: thanks to adamr / FreeDigitalPhotos.internet.

New Microsurgery Robot Helps you to Suture Small Vessels to deal with Lymphedema

At Maastricht UMC+, an instructional hospital within the Netherlands, the very first surgical treatment using a new microrobot continues to be effectively performed. The physicians used a method from Microsure, a Nederlander firm that spun removed from Eindhoven College of Technology and Maastricht UMC+, to suture sub-millimeter vessels within the arm of the patient struggling with lymphedema.

The automatic device converts the movement from the surgeon’s hands into precise, but small actions from the robot, giving physicians an unparalleled degree of skill that might be impossible with only bare hands.

Throughout the surgery, lymphatic vessels which is between .3 and .8 millimeters across were mounted on bloodstream vessels, allowing lymphatic fluid to empty in the area, alleviating painful and harmful swelling.

While this sort of surgery isn’t a break through, along with a couple of surgeons all over the world can carry it out without the assistance of robotics, it remains incredibly difficult. The steadiest of hands still tremble a little and the quantity of focus needed from the physician makes this sort of procedure extremely difficult for many surgeons. The machine basically erases the shaking before transferring the hands movement data towards the robot, maintaining a steadiness that just a robotic can maintain.

“Microsure enables us to be really precise within our movements during procedures that require a surgical microscope,” said Shan Shan Qiu Shoa, cosmetic surgeon at Maastricht UMC+. “Their robot enables us to function on minuscule lymph vessels and bloodstream vessels with increased ease, whilst getting better recent results for these complex and fatiguing interventions. Besides it’s very convenient that, within microsurgery, we are able to work on vessels of each and every size with this particular robot. Most significantly, obviously, this really is great news for that patients concerned.”

Here’s a few videos providing you with phone Microsure automatic system:

Link: Microsure homepage…

Via: Eindhoven College of Technology…

(hat tip: Engadget)

Shandong Weigao to purchase Argon Medical Devices for $850m

MDBR Staff Author Printed 26 September 2017

China-based Shandong Weigao Group Medical Polymer has decided to acquire US-based Argon Medical Devices for approximately $850m.

Shandong Weigao has produced a brand new partnership (JV) through its subsidiary Weigao Worldwide for that purchase of Argon.

Weigao Worldwide owns 90% curiosity about the brand new JV, as the remaining 10% stake is a member of Caymans-based company controlled with a private equity finance firm.

With around 1,200 employees around the world, Argon produces a variety of medical devices for interventional radiology, vascular surgery, interventional cardiology and demanding care procedures.

Argon’s product portfolio includes bone and bone marrow biopsy products, endomyocardial biopsy products, soft tissue and organ biopsy products, in addition to transjugular liver biopsy products.

The organization also produces fluid management systems, urology, vascular and vascular access products.

In Feb this season, Argon has completed the divestment of their critical care business to Merit Medical Systems.

The offer also incorporated the purchase of producing facility in Yishun, Singapore and related commercial operations in Europe and Japan.

Argon stated it divested the company to pay attention to the interventional business around the world.

In 2016, Argon acquired three vascular products from Rex Medical, including OptionELITE retrievable vena cava filter, Cleaner rotational thrombectomy system and UltraStream chronic hemodialysis catheter.

The offer incorporated the purchase of connected ip associated with three products, that have been earlier licensed and written by Argon with an exclusive agreement with Rex Medical.


Image: Shandong Weigao to get US-based Argon Medical Devices. Photo: thanks to adamr / FreeDigitalPhotos.internet.

Medtronic Unveils Concerto 3D Removable Coil System for Peripheral Vasculature


In the ongoing Cardiovascular and Interventional Radiological Society of Europe (CIRSE) meeting in Copenhagen, Denmark, Medtronic has unveiled its new Concerto 3D Removable Coil System. The unit, that is available these days to physicians within the U.S. and Europe, will probably be employed for embolizations within the peripheral arterial blood vessels and veins.

The unit folds right into a dense and knotty shape which will help to complete an aneurysm, for instance, much like how neurovascular aneurysms are actually generally treated. The Concerto 3D also offers small fibers protruding from the size of the Nylon and PGLA coil, which improve turbulence and thus promote clotting that fills in and solidifies an aneurysm.

It is also used along with Medtronic’s Concerto Helix device, which utilizes exactly the same delivery system. Really, the only real distinction between the Concerto Helix and also the Concerto 3D are their shapes.

No pr release can be obtained, but here’s a hyperlink to Medtronic Endovascular…

Editors

At Medgadget, we set of the most recent medical technology news, interview leaders within the field, and file dispatches from medical occasions from around the globe.

PQ Bypass’ trial shows DETOUR system effectiveness to deal with lengthy blockages in femoropopliteal artery

Printed 13 September 2017

PQ Bypass’ DETOUR I medical trial has demonstrated safety and effectiveness from the DETOUR system in treating lengthy-segment (>25 cm) blockages within the femoropopliteal artery

The information were presented like a late breaking medical trial session today at Vascular InterVentional Advances (VIVA 17) by Dr. Sean Lyden, chairman from the department of Vascular Surgery at Cleveland Clinic.

In complex peripheral artery disease (PAD), arterial blood vessels within the leg may become blocked by lengthy segments of plaque that restrict bloodstream flow towards the calf and feet. This may lead to discomfort, lack of mobility and amputation.

Very lengthy blockages, for example individuals more than 20 centimeters, are very difficult to treat. In the past, physicians have treated these blockages with open bypass surgery, that has the advantage of durability however, it’s connected by having an elevated chance of complications, longer hospital stays and prolonged rehabilitation.

Non-invasive methods to PAD, including angioplasty and stenting, work perfectly on shorter blockages however, they haven’t yet been as effective on longer ones.

“Patients with lengthy segment femoropopliteal blockages require advanced therapeutic options to existing treatments. While endovascular revascularization works well in shorter lesions, its durability in longer segment blockages hasn’t matched those of open surgery. Fully percutaneous bypass is made to combine the sturdiness benefits of surgical bypass using the non-invasive benefits of a percutaneous procedure,” stated Dr. Lyden.

“The outcomes there has been within the DETOUR I trial indicate that the fully percutaneous bypass procedure has possibility to fill this gap in treatments.Inches

Case study of the subset from the DETOUR I study presented today at VIVA 17 is among the largest prospective series ever to judge the percutaneous management of femoropopliteal blockages with lengths of 25 cm to 45 cm (mean of 33.8 cm).

 The six-month outcomes from 50 patients shown the DETOUR System’s capability to effectively treat these lengthy blockages without significant effect on venous health insurance and reduced rates of major adverse occasions (MAEs). The outcomes incorporated:

Primary safety endpoint: 2 percent MAEs – understood to be dying, target vessel revascularization (TVR) or amputation at thirty days. There have been no deaths or amputations and something TVR.1

Primary patency of 88.9 % at six several weeks with optimal placement overall primary patency of 76.9 %

Effective delivery of devices towards the identified area and elimination of the delivery system in 100 % of lesions (53/53)

Improvement in Rutherford Class with a minimum of 2 grades in 92 percent of patients (45/49)2

Significant improvement in ankle brachial index from .64 ± .17 to .92 ± .14 (p<0.0001)

No effect on venous function no device-related deep vein thrombosis in treated vessels

Percutaneous femoropopliteal bypass (the DETOUR procedure) is really a recently developed method that utilizes PQ Bypass’ proprietary DETOUR System technologies – TORUS Stent Graft, DETOUR Crossing Tool and DETOUR Snare – to supply fully percutaneous bypass of lengthy-segment blockages within the femoropopliteal artery.

The DETOUR procedure results in a path around a lesion by putting stent grafts that mix in the superficial femoral artery (SFA) in to the femoral vein and into the artery. The brand new path with the stent grafts re-directs oxygen-wealthy bloodstream round the blockage and restores bloodstream flow towards the calf and feet from the patient.

“PQ Bypass has lengthy been dedicated to addressing the requirement for value-based, patient-centered advancements in PAD which help minimize trauma, reduce period of stay and improve recovery occasions, whilst supplying a effective and safe clinical solution of these patients who’re in need of assistance,Inches stated Richard Ferrari, PQ Bypass’ chairman from the board.

“These data demonstrate the potential for the DETOUR procedure in very lengthy SFA lesions. We expect to ongoing our path toward regulatory approval with DETOUR II, a pivotal trial that people anticipate initiating through the finish of the year.”

In March 2017, PQ Bypass received CE (Conformité Européenne) Mark approval for those three devices which are incorporated within the DETOUR System.

VIVA 17 may be the premier global, multidisciplinary course for vascular intervention and medicine, supplying excellence in professional education for those specialties and stakeholders who treat the vascular patient.

Source: Company Pr Release

Study Foreshadows Options of 3D Printing in Medicine


Medgadget has covered a large number of applying 3D printing in medicine, however the field is developing so quickly that the couple researchers believe that clinicians generally aren’t fully conscious of the options. 3D printing, also referred to as additive manufacturing, enables for development of variously formed objects made from unconventional materials that may have qualities which are nearly impossible to create using conventional methods.

Jason Chuen, Director of Vascular Surgery at Austin Health insurance and a Clinical Fellow in the College of Melbourne, and Dr Jasamine Coles-Black, a clinician at Austin Health insurance and research engagement officer at the University of Melbourne, indicate five areas they feel are where 3D printing may have probably the most impact:

  • Bioprinting and Tissue Engineering – manufacture of substitute organs and tissues
  • Pharmacology – new delivery means of drugs promise to enhance compliance making things simpler and much easier for patients
  • Surgical Wedding rehearsal – preparation for complex surgeries could be enhanced considerably using rapidly printed 3D types of relevant anatomy
  • Customized Prostheses – highly detailed, precisely created prosthetic devices that completely fit every individual user may finish up revolutionizing the
  • Distributed Production – areas presently poorly offered by medical manufacturers and distributors risk turning to producing their very own devices in your area

Here’s a hyperlink for their study in The Medical Journal of Australia: Three-dimensional printing in medicine…

Via: College of Melbourne…

Editors

At Medgadget, we set of the most recent medical technology news, interview leaders within the field, and file dispatches from medical occasions from around the globe.

Ethicon Releases PROXISURE Advanced Laparoscopic Suturing Device


Ethicon, a part of Manley and Manley, is releasing within the U.S. its new flagship laparoscopic suturing device, the PROXISURE. It features using curved needles which come within single-use cartridges which slip to the tip from the primary device. The end itself moves in all sorts of ways, articulating 45° both in directions and rotating 360°, all using mechanical operation. The shaft by which the end is manipulated works via a 12 mm trocar.

Getting a curved tip enables the PROXISURE to be effective on flat tissues, the needle naturally extending in to the tissue because it spins round the device’s tip.

The unit itself, though multiple-use, has a restricted existence and it has to eventually become replaced. The cartridges include either Coated VICRYL or ETHIBOND sutures.

Here’s an Ethicon promo video for that PROXISURE:

Product page: PROXISURE Suturing Device…

Via: Ethicon…

Editors

At Medgadget, we set of the most recent medical technology news, interview leaders within the field, and file dispatches from medical occasions from around the globe.

XSTAT Food and drug administration Removed to prevent Gun and Knife Wounds in Legs and arms


RevMedX just announced the Food and drug administration has removed its XSTAT 12 and XSTAT 30 devices to stop severe bleeding from knife and gun-shot wounds within the legs or arms. The XSTAT products are basically large syringes you can use to rapidly push a large number of tablet-sized highly absorbent bits of foam right into a wound. When the foam tablets are within the wound, they rapidly expand, blocking the bloodstream from getting away and delivering pressure to the wound from inside. Each tablet includes a radiopaque marker so it may be easily found using X-ray fluoroscopy during surgery.

Formerly, the XSTAT devices happen to be Food and drug administration approved to be used in civilian and battlefield situations, only to deal with junctional wounds round the groin and shoulders. The brand new indication can help more wounds to become rapidly treated, hopefully preventing arm and leg loss as well as dying.

Here’s a fast demo from the XSTAT getting used on the leg:

Product page: XSTAT…

Flashbacks: Xstat Gunshot Wound System Approved by Food and drug administration to be used on Battlefield… The Best Medical Technologies of 2015… RevMedX Gunshot Hemostasis System and Tourniquet Belt at TEDMED 2014… XStat Gunshot Wound Dressing Removed for Civilian Use within U.S… Johns Hopkins Undergrads Develop Injector to deal with Deep Battlefield Wounds at Junctional Body Sites… XStat Rapid Hemostasis System for Gunshot Wounds Works in 15 Seconds…

Via: RevMedX…

Editors

At Medgadget, we set of the most recent medical technology news, interview leaders within the field, and file dispatches from medical occasions from around the globe.